CompletedPHASE1, PHASE2NCT02931929

MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT

Studying Gastrointestinal stromal tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Medical University Innsbruck
Principal Investigator
Irene Virgolini, Univ-Prof.Dr
Head of department of nuclear medicine
Intervention
68Ga-NeoBOMB1, 2-vial kit(drug)
Enrollment
9 target
Eligibility
21 years · All sexes
Timeline
20162019

Study locations (1)

Collaborators

European Union

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02931929 on ClinicalTrials.gov

Other trials for Gastrointestinal stromal tumor

Additional recruiting or active studies for the same condition.

See all trials for Gastrointestinal stromal tumor

← Back to all trials